T he adaptive growth of blood vessels is an important protective mechanism in patients with chronic vascular occlusive disease. The progressive occlusion of a major artery results in hemodynamic changes and downstream tissue ischemia, which induce both the proliferation of small preexisting collateral arteries and capillary sprouting in ischemic tissue. 1 Recently, transcriptional profiling has been used to investigate the regulatory principles that induce or inhibit adaptive neovascularization, and several key regulators have been identified. 2 However, our current knowledge of transcriptional regulation cannot sufficiently explain the molecular mechanisms of either capillary or arterial growth.
Clinical Perspective on p 1009
In the past years, microRNAs (miRNAs) have been identified as important regulators of gene expression in a wide range of organisms and biological systems. 3 MiRNAs are short (17 to 24 bps), noncoding, single-strand RNA molecules that are transcribed as precursor molecules and are processed to mature miRNAs. MiRNAs are loaded into the RNA-induced silencing complex, which then recognizes sequences located mostly in the 3Ј untranslated regions (UTRs) of target mRNAs via imperfect base pairing, thereby regulating the expression of these genes predominantly by translational repression. Most interestingly, miRNAs can regulate whole groups of functionally related genes and have been shown to target crucial transcription factors and signaling molecules in a large variety of biological processes.
Recent studies suggest an important regulatory function of miRNAs in embryonic and postnatal blood vessel development and in cardiac and vascular diseases. 4 The multidomain protein Dicer is responsible for the processing of miRNA precursor molecules to mature miRNAs, and mice with a homozygous mutation of Dicer die early during embryonic development as a result of vascular defects, suggesting a critical role of miRNAs in embryonic vasculogenesis. 5 Dews et al 6 demonstrated that the transduction of carcinoma cells with the miR-17-92 cluster results in an increased tumor perfusion (mediated predominantly by miR-18 and miR -19) and that modulation of miRNAs can be used to enhance (in this case pathological) tissue perfusion. There is a broad interest in studies on miRNA regulation of tumor angiogenesis, but the role of miRNAs during nonneoplastic blood vessel growth as a compensatory mechanism in vascular occlusive diseases has received little attention so far. Recently, Bonauer et al 7 demonstrated that the specific inhibition of miR-92a by antagomir treatment can be used to improve restoration of hind-limb perfusion in mice.
Here, we explore the changes in miRNA expression during adaptive neovascularization in a mouse model of vascular occlusion. We identify miR-100 as the most consistently downregulated miRNA. It is expressed in endothelial and vascular smooth muscle cells and has inhibitory effects on neovascularization in vitro and in vivo involving the regulation of its target gene mammalian target of rapamycin (mTOR).
Methods
A full Methods section is available in the online-only Data Supplement.
Murine Hind-Limb Ischemia Model
The study conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and was performed after securing appropriate institutional approval. Unilateral femoral artery occlusion was performed in C57/Bl6J mice under anesthesia with ketamine (100 mg/kg) und xylazine (2 mg/kg) by double ligation of the superficial femoral artery proximal to the deep femoral artery and distal femoral artery. Animal numbers are stated with the different experimental results. A sham operation was performed on the contralateral leg.
MiRNA Microarray Analysis
Total RNA was isolated from the distal adductor muscles by phenol-chloroform isolation (TRIzol, Invitrogen, Carlsbad, CA) at 6 time points after femoral artery ligation from 5 mice per time point. RNA was pooled in equal amounts, and microarray analysis for all identified murine miRNAs (miRBase 9.0) was performed by a service provider (LC Sciences, Houston, TX).
In Vivo Antagomir and Rapamycin Treatment
Antagomirs were designed as previously described 8 and custom synthesized (Biozol, Eching, Germany). Mice underwent intravenous tail vein injections of 8 mg/kg antagomir immediately before femoral artery ligation (day 0) and at days 1 and 2. Antagomir sequences were as follows: antagomir-100, 5Ј-cacaaguucggaucuacggguu-3Ј; antagomir control 1, 5Ј-aaggcaagcugacccugaaguu-3Ј; antagomir control 2, 5Ј-caccaguuaggcucuacggauu-3Ј.
For mTOR inhibition, mice were treated with daily intraperitoneal injections of 3 mg/kg rapamycin (sirolimus, LC Laboratories, Woburn, MA) or a combination of rapamycin and intravenous antagomir-100 according to the dosage regimens stated above.
Laser Doppler Perfusion Imaging
For laser Doppler perfusion imaging, the animals were anesthetized and measured under a Periscan PIM II imager (Perimed, Järfälla, Sweden). The readings of 3 individual measurements per mouse were averaged for each time point. Measurements were performed just before and after the operation on day 0 and on days 1, 3, and 7, with the last measurement constituting the main end point. Flow ratios of the occluded/nonoccluded leg were compared between the treatment groups.
Statistical Analysis
Data are expressed as mean and SEM. Treatment groups were compared by unpaired Student t test with Prism 4 for Windows (GraphPad Software Inc, San Diego, CA). One-way ANOVA was used for multiple comparisons of Ͼ2 groups.
The Bonferroni posthoc test for multiple comparisons was used if the P value for the overall ANOVA comparison was statistically significant. Because normal distribution of our data could not be statistically verified owing to sample size, additional nonparametric testing was performed with Mann-Whitney U tests (for 2 groups) or Kruskal-Wallis tests (for Ͼ2 groups), which confirmed the statistical significance of our findings. Values of PϽ0.05 were considered statistically significant.
Results

Microarray Results and miR-100 Expression Pattern
To assess the changes in the miRNA transcriptome after femoral artery occlusion, miRNA microarray analysis was performed with total RNA isolations of the adductor muscle group from the distal thigh at baseline and 5 time points after ligation of the femoral artery. After filtering the data for low gene expression and applying a statistical threshold of PϽ0.05 for differential expression over all time points (ANOVA), we selected candidates for further analysis on the basis of their change in expression at day 3 after femoral artery occlusion compared with baseline expression before induction of ischemia. A total of 40 upregulated and 42 downregulated miRNAs fulfilling these criteria were identified.
Confirming the validity of our experimental approach, the top 15 upregulated and downregulated miRNAs include several candidates previously described to be involved in blood vessel growth and development or other aspects of vascular biology (Tables 1 and 2 ). Indeed, one of the genes with the highest increase in expression is miR-92 (renamed miR-92a according to the newest miR base definition); its importance as an angiogenic modulator was recently described in several animal models, including murine hind-limb ischemia. 7 The complete time course of expression of all 82 differentially regulated miRNAs is listed in Tables II and III in the online-only Data Supplement.
Besides the upregulated miRNAs, the top 15 downregulated miRNAs at day 3 also include several previously characterized miRNAs with regulatory functions in vascular proliferation such as several members of the let-7 family. The miRNA that was most consistently downregulated at day 3 after femoral artery occlusion followed by a recovery of expression until day 14 was miR-100 ( Figure 1A ). Because of this finding, and because it has not been studied before in the context of blood vessel growth, we selected miR-100 for further investigation.
Quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) using miRNA stem loop primers for miR-100 at different time points after femoral artery ligation confirmed our microarray data ( Figure 1B ). Using in situ hybridization in combination with immunofluorescent staining for vas-cular markers, we found that miR-100 is highly expressed in endothelial cells ( Figure 1C ). A hybridization probe against miR-159 was used as a negative control because it is known that this miRNA is not expressed in murine tissue. However, miR-100 is not expressed exclusively in capillary endothelial cells. Expression could also be detected in vascular smooth muscle cells, perivascular cell populations, and skeletal muscle cells. To confirm that the observed changes in expression were indeed related to vascular structures, we isolated collateral arteries from murine hind limbs at 3 days after femoral artery occlusion for RT-PCR analysis. Indeed, miR-100 is expressed in both the growing collateral arteries (proliferation verified by Ki67 expression; not shown) and the nonproliferating arterial anastomoses from the nonoccluded hind limb. However, miR-100 expression is significantly decreased in growing collateral arteries compared with the quiescent blood vessels from the sham-operated side ( Figure 1D ). In addition, we further separated cell populations from ischemic hind-limb tissue by isolating CD31-positive cells using antibody-bound magnetic beads, yielding an almost pure endothelial cell population ( Figure 1E ). Although miR-100 expression decreases in both endothelial and nonendothelial cell populations, the strongest downregulation was detected in the CD31-positive endothelial cells. Taken together, these results show that miR-100 is expressed in blood vessels and is significantly downregulated in vascular cells from ischemic tissue.
Modulation of miR-100 Expression in Cultured Endothelial and Vascular Smooth Muscle Cells
To verify the expression of miR-100 in pure cell populations of the vascular wall, we used stem-loop RT-PCR for total RNA isolates from cultured human endothelial cells (human umbilical vein endothelial cells) and human aortic vascular smooth muscle cells. As expected, miR-100 is strongly expressed in both cell types, with a relatively fast decrease in expression on inhibition of miRNA transcription by addition of actinomycin D ( Figure IA and IB in the online-only Data Supplement).
To investigate a potential role of miR-100 in angiogenesis, we overexpressed or silenced miR-100 in endothelial cells by transfecting specific miR-100 precursors (pre-miRs) or antisense oligonucleotides (anti-miRs), respectively. An optimized transfection protocol using fluorescent control pre-miRs and anti-miRs resulted in a transfection efficiency of endothelial cells of Ͼ90% ( Figure IC in the online-only Data Supplement). Quantitative RT-PCR revealed a strong increase in detectable miR-100 at 24 hours after pre-miR-100 transfection, whereas transfection with anti-miR-100 resulted in significantly decreased miR-100 levels ( Figure ID In contrast, the reduction of miR-100 levels by transfection of specific anti-miRs had a stimulatory effect in both assays, resulting in increased endothelial network formation and a longer total sprout length (Figure 2A and 2B) .
Because adaptive vascular growth includes the proliferation and migration of both endothelial and smooth muscle cells, we analyzed the DNA synthesis rate by measuring BrdU incorporation and migratory speed in the planar cell migration assay in these cell types. We detected an attenuation of endothelial cell proliferation by pre-miR-100 transfection, whereas inhibition of miR-100 by anti-miRs had a consistent stimulatory effect ( Figure 2C) . The inhibitory effect of pre-miR-100 transfection was more pronounced in endothelial cells than in smooth muscle cells, possibly because of the lower baseline levels of miR-100 in these cells ( Figure 2D ). Notably, migratory speed of endothelial cells was not affected by miR-100 modulation, but inhibition of miR-100 had a significant stimulatory effect on vascular smooth muscle cell migration, which is a key process in the enlargement of preexisting anastomoses to collateral arteries ( Figure II in the online-only Data Supplement).
Taken together, these findings show that miRNA-100 has antiangiogenic and antiarteriogenic properties in endothelial and vascular smooth muscle cells.
MiR-100 Targets mTOR in Vascular Cells
Knowing that miR-100 regulates vascular cell sprouting and proliferation, we asked how these effects can be achieved. To identify potential target genes of miR-100 that may confer the observed effects of miR-100, we used a combination of bioinformatic prediction algorithms and microarray-based gene expression analysis. MiR-100 was overexpressed in endothelial cells, and regulated mRNAs were identified by cDNA microarray analysis. The genes with the strongest difference in expression are shown in Table IV in the online-only Data Supplement. Because miRNAs function primarily by mRNA repression, we were particularly interested in downregulated mRNAs because they may be direct miRNA targets.
After pre-miR-100 overexpression, a total of 581 genes were significantly downregulated with a Ͼ1.5-fold difference in log intensity. Among these genes, we screened for potential miRNA seed sequences in the 3Ј UTR by 2 bioinformatic algorithms (TargetScan [www.targetscan.org] and miRanda [www.microrna.org]) and identified 8 differentially expressed genes with an miR-100 target site predicted by both algorithms (Figure 3A and 3B ). Of these candidates, we chose the mTOR (coded by the FRAP1 gene) for further analysis because of its strong association with proangiogenic signaling. 9 First, we demonstrated that overexpression of miR-100 represses mTOR expression on both the mRNA and protein levels in endothelial cells, whereas miR-100 inhibition resulted in a modest but significant upregulation of mTOR ( Figure 3C through 3E) . Confirming our findings, the binding site of miR-100 in the 3Ј UTR of mTOR was characterized and experimentally verified by another group during the course of our study. 10 Next, we investigated the functional role of mTOR in miR-100 signaling. Therefore, we transfected 2 different mTOR-coding plasmids, containing or not containing the 3Ј UTR, in combination with pre-miR-100. Because of the large size of the mTOR expression plasmids, we were unable to achieve sufficient transfection rates in endothelial cells without procedure-related toxicity. However, we then chose the easily transfectable HEK 293 cells as a culture model, in which we could reproduce the miR-100 effects on proliferation seen in endothelial cells ( Figure 3F ). Supporting the notion that mTOR is involved in miR-100 signaling, a complete rescue could be achieved by expressing the mTOR open reading frame lacking the miR-100 binding site. In contrast, the overexpression of full-length mTOR including the 3Ј UTR rescued the miR-100 effect only partially. To exclude potential differences in transfection efficiency between the 2 mTOR plasmids as a confounder, we analyzed the mTOR plasmids levels 24 hours after transfection by quantitative PCR for mTOR cDNA and found no significant difference ( Figure III in the online-only Data Supplement). Third, to test whether miR-100 also regulates mTOR in vivo, we first performed immunofluorescent stainings for mTOR on tissue sections obtained from ischemic hind limbs, knowing that in these conditions miR-100 is downregulated. As expected, these specimens stained positive for mTOR, with the strongest staining in endothelial cells and a slightly lesser staining in vascular smooth muscle cells ( Figure IV in the online-only Data Supplement). Subsequently, we isolated the endothelial cells from the ischemic hind-limb tissue and the contralateral hind limb and quantified mTOR expression by real-time PCR. Expression of this miR-100 target molecule was indeed upregulated in response to hind-limb ischemia, and its expression could be increased further by inhibition of miR-100 expression in vivo by antagomir treatment. These data suggest that miR-100 regulates mTOR expression not only in vitro but also in vivo ( Figure IV in the online-only Data Supplement). In summary, we demonstrate that mTOR is a target of miR-100 in vascular cells and that it conveys its effect on cell proliferation.
Inhibition of miR-100 In Vivo by Antagomir Treatment Stimulates Perfusion Restoration in Mice
On the basis of our previous results, our next aim was to test whether inhibition of miR-100 stimulates revascularization in vivo. Therefore, we treated mice immediately before and for 2 days after induction of unilateral hind-limb ischemia with a specific antagomir targeted against miR-100. Fluorescencelabeled antagomir could be found in the endothelial layer of blood vessels ( Figure VB As expected, antagomir-mediated inhibition of miR-100 resulted in stimulation of perfusion restoration after hindlimb ischemia as measured by laser Doppler imaging ( Figure  4) . Flow ratio at day 7 after induction of ischemia was higher in antagomir-100 -treated animals compared with treatment with either of 2 control antagomirs: one constituting a random sequence that was previously shown to be without effect on perfusion restoration in this model (antagomir control 1; Figure 4A and B) 7 and one designed to represent a scrambled version of the anti-miR-100 antagomir (antagomir control 2; Figure VI in the online-only Data Supplement). Increased vascularization after miR-100 antagomir treatment was also . miR-100 inhibition by antagomir treatment stimulates perfusion restoration after hind-limb ischemia in vivo. Intravenous antagomir-100 injection (8 mg/kg) resulted in a strong decrease of miR-100 levels to almost undetectable levels by stem-loop RT-PCR at 24 hours after injection. A and B, Laser Doppler perfusion measurements revealed a significant stimulation of blood flow recovery at day 7 after femoral artery ligation by antagomir-100 treatment (nϭ10) compared with a control antagomir previously shown to be without effect (antag-cont1; nϭ10). C and D, Antagomir-100 treatment resulted in a significant increase in vascular density in the gastrocnemius muscle compared with treatment with a control antagomir (C and D). Capillaries are shown in the overlay by a red CD31 staining; smooth muscle cells are stained by FITC-labeled smooth muscle (SM) actin antibody (green); and nuclei are stained in blue (DAPI). E and F, As a second in vivo angiogenesis assay, Matrigel was injected subcutaneously in mice treated with antagomir against miR-100 or control antagomir. Matrigel plugs were harvested after 14 days, and the depth of cellular infiltration was quantified histologically. Measurements of cellular invasion depth (E and F) and hemoglobin content (G) revealed a significant stimulation of Matrigel vascularization by antagomir-100 treatment. ROI indicates region of interest. *PϽ0.05 vs the corresponding control.
detectable morphologically, with an increase in the density of capillary and arterial blood vessels in the distal hind-limb tissue ( Figure 4C and 4D) .
To assess whether miR-100 can modulate blood vessel formation also in the absence of ischemia, we performed the Matrigel plug assay as a second model of in vivo neovascularization. Parallel to ischemic conditions, antagomir-100 treatment resulted in a significant stimulation of vascularization of subcutaneously implanted Matrigel plugs, as quantified by higher hemoglobin content of the Matrigel implant and a deeper endothelial invasion zone in antagomir-100 -treated animals compared with controls ( Figure 4E and 4F) .
Because we have shown that miR-100 is downregulated under ischemic conditions and that downregulation of miR-100 has proproliferative effects, which are conferred by mTOR, we aimed to investigate the effects of direct pharmacological mTOR inhibition by rapamycin. Thus, we treated 2 separate groups of mice with either daily injections of the mTOR inhibitor rapamycin or solvent to investigate the time course of hind-limb perfusion restoration under conditions of endogenous miR-100 downregulation and impaired signaling of its target gene mTOR. In addition, a third group of animals were treated with a combination of intravenous antagomir infusions against miR-100 and daily intraperitoneal injections of rapamycin to assess whether the stimulatory effect of miR-100 inhibition on perfusion restoration is mTOR dependent. Confirming our hypothesis, rapamycin treatment alone resulted in a significant attenuation of blood flow restoration at day 7 after femoral artery ligation and a decreased capillary density in the ischemic tissue compared with the solvent-treated group (Figure 5 ). In addition, the stimulatory effect of antagomir therapy was abolished by simultaneous rapamycin treatment, demonstrating that the therapeutic effect of miR-100 inhibition in hind-limb ischemia Figure 5 . mTOR inhibition attenuates perfusion restoration after femoral artery ligation. A, Treatment of mice after femoral artery ligation with the specific mTOR inhibitor rapamycin resulted in a significant reduction of laser Doppler flow at day 7 after femoral artery ligation (nϭ10) and a significantly reduced capillary density at day 14 (B; nϭ5). In addition, rapamycin treatment abrogated the stimulatory effect of antagomir-100 injection, showing that the therapeutic effect of miR-100 inhibition is dependent on intact signaling of its target molecule mTOR. C, Real-time PCR-based analysis of isolated endothelial cells from ischemic hind limbs revealed that mTOR expression is inversely correlated with miR-100 expression levels, upregulated in response to hind-limb ischemia, and further increased after miR-100 inhibition in ischemic hind limbs. *PϽ0.05 vs the corresponding control.
is dependent on the intact signaling ability of its target gene mTOR.
Taken together, these results show that miR-100 inhibition enhances vascularization involving the upregulation of mTOR in vivo.
Discussion
We describe for the first time the downregulation of miRNA-100 after induction of ischemia in vivo and the function of this miRNA as an antiangiogenic modulator in endothelial and vascular smooth muscle cells. In addition, we demonstrate the regulation of mTOR levels by miR-100 in vascular cells and an important role of this central signaling molecule as a downstream mediator of miR-100 effects.
MiR-100 was first described as a small endogenous RNA in 2002 11 and subsequently was found to be differentially regulated in several studies on tumor expression patterns. [12] [13] [14] It is localized on chromosome 11 in a cluster with let7a-2 and forms an miRNA family with the sequence-related miR-99. In the cardiovascular field, miR-100 was first mentioned in a report by Sucharov et al 15 showing a significant upregulation of miR-100 in tissue samples from failing hearts of patients with idiopathic dilated cardiomyopathy. Besides these differential expression results, very little is known about the function of miR-100. Recently, Henson and coworkers 16 described a decreased expression of miR-100 in oral squamous cell carcinoma, and related to this, they observed reduced cell proliferation after pre-miR-100 transfection. This finding is in good agreement with our results in endothelial and vascular smooth muscle cells ( Figure 2) .
The functional importance of miR-100 in cancer biology is further supported by a recent report showing that decreased expression of miR-100 in human nasopharynx carcinoma cells results in disease progression and correlates with higher levels of the mitotic regulator polo-like kinase 1, suggesting that miR-100 may be involved in regulation of cell proliferation. 17 The function of miR-100 in the vascular system has not been investigated so far, and to the best of our knowledge, we report here the first study applying differential expression results from an in vivo study to identify a novel miRNA regulator of neovascularization.
Although most recent studies on "angio-miRs" have used a miRNA transcriptome analysis of cultured endothelial cells for their primary selection of candidate miR-NAs, 7, 18 we pursued an alternative approach that is closely related to the clinical situation of peripheral artery disease. Our research group has a longstanding interest in the regulation of blood vessel growth, and we use the hindlimb ischemia model as one of several in vivo models. 19, 20 To identify novel regulators of neovascularization, we aimed to unravel the temporal changes of miRNA expression in the widely used neovascularization model of murine femoral artery ligation. Our microarray screen yielded many differentially expressed miRNAs of potential interest, among them several with a previously described regulatory function in blood vessel growth. Indeed, the strong upregulation of miR-92 is in good correspondence with another recent report using the same experimental model. 7 In addition, we found several miRNAs with a known function in vascular biology such as miR-21 21 and members of the let-7 family that have been investigated extensively in other vascular disease models, suggesting a significant overlap in miRNA expression patterns among the different experimental approaches. This fact underscores the relevance of our screening approach and makes an important function of novel candidates likely.
Besides miR-100, we identified several potentially interesting miRNAs that until now have not been characterized functionally in blood vessel growth and therefore constitute promising candidates for future studies (see Tables 1 and 2 ). For example, little is known in this context about the role of miR-143, which is known to be strongly expressed in vascular smooth muscle cells 22 and strongly upregulated in our screen. Another miRNA with a potentially important role in adaptive vessel growth could be miR-223, which showed the strongest upregulation at day 3 after femoral artery ligation. This miRNA is expressed predominantly in bone marrow-derived cells, a cell population known to be of great importance for neovascularization after hind-limb ischemia. 23 Although miR-100 is not the miRNA with the strongest deregulation after induction of hind-limb ischemia, its downregulation is most consistent over time, and it is highly expressed in vascular cells. We found miR-100 to be expressed in endothelial and vascular smooth muscle cells in blood vessels in vivo and in isolated vascular cells in cell culture. By modulating miR-100 levels with both loss-of-function and gain-of-function approaches in vitro, we demonstrate a regulatory function of this miRNA in several established angiogenesis models such as endothelial sprouting and branching in vitro and the Matrigel plug assay in vivo, as well as in more general cellular processes such as proliferation.
Following these findings, we aimed to elucidate the mechanism of the observed miR-100 effects and chose a combined analysis of miR-100 -modulated gene expression on transcript level and bioinformatic target site prediction. Although the predominant effect of most miRNAs is seen on translation and not transcript stability, we chose this approach because of technical feasibility and because it has previously been used successfully to unravel miRNA target gene interaction in heart failure. 24 The obtained short list of genes that both were downregulated after miR-100 overexpression and contained a potential target site for this miRNA included mTOR. This gene is required for angiogenesis and endothelial cell proliferation in response to hypoxia, 9, 25 and is one of the promising targets for novel antiangiogenic cancer therapies. 26, 27 Here, we demonstrate that mTOR is negatively regulated by miR-100 in endothelial cells. In addition, we show that miR-100 is able to repress mTOR-dependent cellular proliferation and that this effect can be neutralized by expressing mTOR lacking the miR-100 binding site.
Because our microarray-based screen for miR-100 target genes in endothelial cells systematically neglected genes that are regulated on the protein level only, our data do not exclude other miR-100 target genes as mediators of the observed effects on neovascularization. However, our results show that the repression of mTOR is both necessary and sufficient to attenuate cellular proliferation.
To investigate the in vivo significance and the potential relevance of miR-100 as a therapeutic target, we treated mice with an antagomir against miR-100. Using this approach, we confirmed our in vitro results of miR-100 as an inhibitor of neovascularization and the stimulatory effect of miR-100 inhibition on blood vessel proliferation. In addition, and in good agreement with our cell culture results, inhibition of mTOR resulted in the opposite effect on hind-limb perfusion restoration compared with miR-100 antagomir treatment. If mTOR signaling is inhibited by rapamycin, the stimulatory effect of antagomir-100 treatment is abrogated, demonstrating that the therapeutic effect of miR-100 inhibition is mTOR dependent.
Compared with other studies on the stimulation of angiogenesis by antagomir treatment, 7 the therapeutic effects achieved by miR-100 inhibition are relatively modest. Although direct comparisons with other research groups using the hind-limb ischemia model are difficult because of inevitable methodological differences, one explanation could be that, in contrast to, for example, the upregulated miR-92a, miR-100 is spontaneously downregulated after the induction of ischemia. Therefore, the benefit of additional miR-100 inhibition will probably reach a ceiling effect.
Future studies, especially in coronary artery disease models, are necessary to validate the possible therapeutic use of miR-100 inhibition. In addition, given the known importance of the miR-100 target molecule mTOR in many different physiological processes, possible side effects of miR-100 inhibition, especially with regard to the immune response, also need to be investigated.
Our study adds a new candidate to the list of described "angio-miRs" and illustrates the role of miR-100 as an endogenous mTOR modulator in the regulation of cellular proliferation and neovascularization. Although many technical aspects and especially safety issues remain to be solved, miR-100 could be a promising new target for pharmacological therapy in cardiovascular and neoplastic disease.
